|
Age at diagnosis
|
|
40–44 years
| |
Reference
| |
|
45–49 years
|
0.542
|
0.932
|
0.741–1.170
|
|
50–54 years
|
0.878
|
1.017
|
0.821–1.260
|
|
55–59 years
|
0.024
|
1.270
|
1.032–1.562
|
|
Race
|
|
White
| |
Reference
| |
|
Black
|
0.001
|
1.317
|
1.127–1.540
|
|
Other a
|
0.128
|
1.192
|
0.951–1.495
|
|
Marital status
|
|
Single
| |
Reference
| |
|
Married
|
0.008
|
0.819
|
0.707–0.949
|
|
Other b
|
0.130
|
0.871
|
0.728–1.042
|
|
Insurance (yes vs no)
|
< 0.001
|
0.587
|
0.459–0.751
|
|
Histology
|
|
Ductal
| |
Reference
| |
|
Lobular
|
0.744
|
1.041
|
0.820–1.321
|
|
Others
|
0.356
|
1.105
|
0.894–1.365
|
|
Laterality
|
|
Right
| |
Reference
| |
|
Left
|
0.506
|
1.043
|
0.921–1.182
|
|
Bilateral, single primary
|
0.177
|
2.21
|
0.894–1.365
|
|
Grade
|
|
I
| |
Reference
| |
|
II
|
0.309
|
1.147
|
0.881–1.492
|
|
III or IV
|
< 0.001
|
1.960
|
1.491–2.577
|
|
Tumour subtype
|
|
HR+/HER2-
| |
Reference
| |
|
HR+/HER2+
|
0.002
|
0.631
|
0.474–0.839
|
|
HR−/HER2-
|
< 0.001
|
2.808
|
2.169–3.634
|
|
HR−/HER2+
|
0.258
|
0.716
|
0.401–1.277
|
|
Site of metastases
|
|
Lung (yes vs no)
|
0.020
|
1.378
|
1.188–1.598
|
|
Liver (yes vs no)
|
< 0.001
|
2.085
|
1.795–2.422
|
|
Brain (yes vs no)
|
< 0.001
|
1.903
|
1.542–2.248
|
|
Surgery (yes vs no)
|
< 0.001
|
0.504
|
0.431–0.590
|
|
HR+/HER2- * multi-metastases
| |
Reference
| |
|
HR+/HER2+ * multi-metastases
|
0.045
|
0.694
|
0.485–0.992
|
|
HR−/HER2- * multi-metastases
|
0.717
|
0.941
|
0.675–1.310
|
|
HR−/HER2+ * multi-metastases
|
0.564
|
0.828
|
0.437–1.572
|
|
Next step
|
|
White*HR+/HER2-
| |
Reference
| |
|
Black*HR+/HER2+
|
0.366
|
0.821
|
0.536–1.258
|
|
Other a*HR+/HER2+
|
0.652
|
0.862
|
0.453–1.641
|
|
Black*HR−/HER2-
|
0.323
|
0.817
|
0.546–1.220
|
|
Other a*HR−/HER2-
|
0.299
|
1.508
|
0.695–3.271
|
|
Black*HR−/HER2+
|
0.696
|
0.881
|
0.466–1.664
|
|
Other a*HR−/HER2+
|
0.368
|
0.701
|
0.323–1.521
|
